AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting

Trending Investment Opportunities

The European Commission has approved AstraZeneca Plc AZN and Daiichi Sankyo's DSNKY Enhertu as monotherapy for unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
The approval is based on results from the DESTINY-Breast03 Phase 3 trial, in which Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1).
Additional results from the DESTINY-Breast03 Phase 3 trial showed that in the secondary endpoint of overall survival (OS), there was a strong trend towards improved OS with Enhertu; however, this analysis is not yet mature and further follow-up is ongoing.
Related: Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer.
Nearly all patients treated with Enhertu were alive at nine months compared to 91.3% of patients treated with T-DM1. The confirmed objective response rate was more than doubled in the Enhertu arm versus the T-DM1 arm (79.7% vs. 34.2%).
Following EU approval, AstraZeneca will pay $75 million to Daiichi Sankyo as a milestone payment.
Price Action: AZN shares are up 1.46% at $67.34 during the premarket session on the last check Tuesday.